Thu, Aug 28, 2014, 8:00 AM EDT - U.S. Markets open in 1 hr 30 mins


% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • tlrohrbach1946 tlrohrbach1946 Apr 25, 2014 11:17 AM Flag

    What is Merck waiting for?


    Assuming Merck is going to buy out Oncs, what are they waiting for? What is Merck thinking about? Are the Cutaneous Lymphoma results going to be the main impetus for such a buyout? They could buy Oncs with either newly issued shares or treasury shares of their own stock and not put out a dime of cash; either a share for share swap or two Oncs for one Merck. Merck is currently selling around $57 and $58 and if they swap, by my estimates there will be a dilution effect on the Merck stock price 7-10% on a one for one swap. Any dilution affect would likely be short lived. If I was Merck that is what I would try to do since it would not be like giving up any of Merck’s physical assets, namely cash, but simply issuing board of director’s approved pieces of paper in the form of new common stock certificates in exchange for Oncs shares. They would be getting all of Oncs cash, any significant license agreements, patents, and other assets from such an exchange basically for free and only get out the check book maybe to pay some small legal fees. If Oncs comes to fruition in a few years with their treatments, it would likely put Merck’s related drugs and treatments out of business. So if you were Merck, what would you do? When also is it the best time for Merck to buy out Oncs? After maybe some presentations and Oncs gets another big cash infusion from some highly interested new heavy hitter investors putting more cash into Oncs coffers? Then also Oncs has to show that the electroporation works big time too. Exactly when is that clear? Would any of Merck’s competitors jump on Oncs if Merck doesn’t strike while the iron while it is hot? As an Oncs stockholder I have been waiting for that special moment of ca-ching for just over two years now. Is now the time?

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ASSuME, thanks a lot. Where have you ever heard anything, even a rumor Merck was going to buy out ONCS? Why would a large well developed pharmaceutical company buyout a development stage pharm company that has not yet proven their theory in trials? The rumor, and well established path that ONCS is taking, the CEO has spoken of multiple times is a partnership, not a buyout. Merck is waiting for ONCS to offer/finalize it, ONCS is waiting for P2 data to be released and to be in a spot where the P2b trials are ready to begin. Lets be patient, and stick with the grounded and bright future that ONCS does have and has talked about, and stay away from baseless speculation.

    • I'm sure MRK is doing a ton of DD. They wouldn't be where they are by making knee jerk decisions. I wouldn't make the assumption this will happen no matter what has been said or posted. We would all like to see this happen but it's obviously no slam dunk. I'm sure MRK is looking for more results before they do anything.

0.4422+0.0032(+0.73%)Aug 27 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TubeMogul, Inc.
NasdaqGSWed, Aug 27, 2014 4:00 PM EDT
Abercrombie & Fitch Co.
NYSEWed, Aug 27, 2014 4:03 PM EDT